MARK3

Across TCGA pan-cancer cohorts, MARK3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MARK3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MARK3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MARK3 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

HNSC, CCRCC, and COAD are the cancer types where MARK3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MARK3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.415	<.001	12	view →
CCRCC	Male	IV	−0.337	<.001	12	view →
COAD	All	All	−0.150	<.001	7	view →
PDAC	All	All	−0.213	<.001	6	view →
LSCC	Male	II,III,IV	+0.181	<.001	6	view →
LUAD	Female	All	−0.080	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MARK3–HNSC

Open the HNSC breakdown →